loader
Please Wait
Applying Filters...

Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    List of Certificates of Suitability (CEPs) for r0_cep_2015_224___rev_00 Active Pharmaceutical Ingredient (API) issued by the EDQM. Original Data: EDQM Database

    Client Virtual Booth
    Menu

    Kores India Limited

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    INTERMEDIATES

    PharmaCompass

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Send me more info on How To Grow My Business Digitally?

    Left Arrow
    Right Arrow
    Filters Filter
    Cross PopUp
    FILTER :

    filter

    01 KORES (INDIA) LIMITED Navi Mumbai IN (1)

    filter

    01 Glimepiride (1)

    filter

    01 India (1)

    filter

    01 Withdrawn by EDQM Failure to CEP procedure (1)

    ListList of Suppliers
    refresh Reset Filter
    refresh Reset Filter
    product-page Supplier Virtual Booth
    price-trend Ask Us

    KORES (INDIA) LIMITED Navi Mumbai I...

    Contact Supplier
      Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
      Post an Enquiry Post an Enquiry
      Flag India
      Virtual Booth Virtual Booth
      Digital Content Digital Content

      Glimepiride

      PDF Supplier PDF
      URL Supplier Web Content
      R0-CEP 2015-224 - Rev 00
      Withdrawn by EDQM F...
      Chemical
      2016-08-19
      2018-12-18
      2223
      ASK
      US
      PHARMACOMPASS
      Upload
      your Marketing & Sales content

      Looking for Certificates of Suitability (CEPs) for R0-CEP 2015-224 - Rev 00 of Kores (india) Limited Navi Mumbai In

      Looking for Certificates of Suitability (CEPs) for R0-CEP 2015-224 - Rev 00 of Kores (india) Limited Navi Mumbai In 1

      20

      Kores (india) Limited Navi Mumbai In, based in India, is a pharmaceutical company.

      One of their significant offerings is Glimepiride, supported by a 'Withdrawn by EDQM Failure to CEP procedure' Certificate of Suitability (CEP) with the number R0-CEP 2015-224 - Rev 00

      This Chemical Type CEP, issued on August 19, 2016, remains in force until December 18, 2018, ensuring its reliability within the pharmaceutical industry.

      Substance Number 2223 associated with this CEP further emphasizes

      Post Enquiry
      POST ENQUIRY